Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 2,253 Cr.
- Current Price ₹ 51.4
- High / Low ₹ 65.3 / 11.7
- Stock P/E 188
- Book Value ₹ 1.50
- Dividend Yield 0.02 %
- ROCE 21.8 %
- ROE 15.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 244% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.6%
- Debtor days have improved from 135 to 98.2 days.
Cons
- Stock is trading at 34.2 times its book value
- Earnings include an other income of Rs.5.30 Cr.
- Working capital days have increased from 201 days to 404 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 35 | |
| 5 | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 23 | |
| Operating Profit | -0 | -0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 12 |
| OPM % | -2% | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 39% | 35% |
| 0 | 1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 |
| Profit before tax | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 13 |
| Tax % | 9% | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | 28% | |
| -1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 12 | |
| EPS in Rs | -0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.10 | 0.42 | 0.22 | 0.26 |
| Dividend Payout % | 0% | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% | 5% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 22% |
| 3 Years: | 17% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 53% |
| 5 Years: | 244% |
| 3 Years: | 134% |
| TTM: | -17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 64% |
| 5 Years: | 193% |
| 3 Years: | 321% |
| 1 Year: | 211% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 22% |
| 3 Years: | 27% |
| Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 |
| Reserves | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 22 |
| 0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 4 | |
| 4 | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 18 | |
| Total Liabilities | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 87 |
| 10 | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 19 | |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 66 | |
| Total Assets | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 87 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3 | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | |
| -10 | 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | |
| -18 | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | |
| Net Cash Flow | -31 | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 | 6 | 2 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45 | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 |
| Inventory Days | 134 | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 |
| Days Payable | 209 | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 |
| Cash Conversion Cycle | -30 | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 |
| Working Capital Days | 368 | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 404 |
| ROCE % | -6% | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% | 22% |
Documents
Announcements
- Voting Result Along With Scrutinizer Report Of Postal Ballot 23h
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
1d - Signed non-binding MOU Jan 5, 2026 with Borns Medical Robotics to commercialize AI surgical robots in India, via Shukra Robotics.
-
Reconstitution Of Committees Of The Company.
30 Dec - Bhoomi Patel resigned; Dinesh Chauhan appointed Independent Director effective Dec 30, 2025; committees reconstituted.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
30 Dec - Resignation of Independent Director Bhoomi Patel; appointment of Dinesh Chauhan effective Dec 30, 2025; committees reconstituted.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 Dec - Mr Dinesh Chauhan appointed Additional Independent Director; Ms Bhoomi Patel resigned; committees reconstituted—effective Dec 30, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies